Brunna Xavier Martins

Lytic cell death pathways drive hepatic ischemia-reperfusion injury (IRI). The transmembrane protein ninjurin-1 (NINJ1) aggregates in the plasma membrane to permeabilize the cell during multiple cell death pathways implicated in hepatic IRI. We hypothesized that NINJ1 mediates liver IRI and that its inhibition would mitigate injury. We found that NINJ1 is highly expressed in human liver tissue and that its up-regulation and activation correlate with early allograft dysfunction in liver transplant patients. Using a segmental hepatic IRI model in mice and rats, Ninj1 genetic deletion or pharmacologic inhibition diminished acute injury. Mice with hepatocyte- or macrophage-specific Ninj1 knockout had reduced hepatocellular injury following IRI, suggesting that NINJ1 within both populations contributes to the resulting liver injury. Mechanistically, we found that hepatocytes and Kupffer cells are susceptible to hypoxia-induced NINJ1-mediated plasma membrane rupture, which can be pharmacologically prevented. We therefore position NINJ1 as a potential new therapeutic target to limit hepatic IRI, with important implications for liver transplantation.

A bstract: Phenotypic, genetic and metabolic tumour heterogeneity is a major factor contributing to cancer progression, metastasis, and resistance to therapy. Distinctive thermal and proton flux patterns can occur in cancer cells as a function of variations in the metabolic rate of the tumour mass, tumour margins, and normal tissues, which can be detected by video thermometry (VTM) as well as by Scanning Ion-selective Electrode Techniques (SIET). This study presents distinct thermal patterns associated with tumour heterogeneity observed in canine mammary cancer using VTM and investigate the correlation between these thermometric signatures with metabolic changes related to V-ATPase activity by comparing real-time VTM data with that from concanamycin-sensitive ATP hydrolysis and cell proton flux measurements. The results demonstrate that integrating SIET and VTM data sets can reveal metabolic signatures to assist the diagnosis, surgery and therapeutic monitoring. Considering the breast cancer hallmarks conservation in human, canines and other mammals, this study provides a first bioenergetic proof-of-concept for the potential of the integration of the VTM technology with enzymatic and electrophysiological analyses sensitive to concanamycin for the development of more effective diagnostic, prognostic and therapeutic approaches in veterinary as well as in preclinical medical studies.

Hepatic ischemia-reperfusion injury (IRI) results from interrupted perfusion to the liver and contributes to acute liver dysfunction such as following liver transplantation. Lytic cell death pathways are major drivers of IRI and the subsequent inflammatory response. The transmembrane protein ninjurin-1 (NINJ1) was identified as the key executor of terminal plasma membrane rupture across multiple lytic cell death pathways implicated in hepatic IRI. We hypothesized that NINJ1-mediated lytic cell death drives IRI and that its therapeutic inhibition would mitigate liver IRI. Using human liver specimens, we found that NINJ1 is highly expressed in human liver tissue and that its activation correlates with early allograft dysfunction in patients undergoing liver transplantation. Utilizing a segmental hepatic IRI model in mice and rats, Ninj1 genetic deletion or pharmacologic inhibition diminished acute liver injury. Mice with hepatocyte- or macrophage-specific Ninj1 knockout both had reduced hepatocellular injury following IRI, suggesting that NINJ1 within both populations contributes to the resulting liver injury. Mechanistically, we found that hepatocytes and Kupffer cells are highly susceptible to hypoxia-induced NINJ1-mediated plasma membrane rupture, which can be pharmacologically prevented. These data position NINJ1 as a potential new therapeutic target to limit hepatic IRI, with important implications for organ preservation during liver transplantation.